Aspect Biosystems, a Vancouver, British Columbia-based biotechnology company advancing microfluidic 3D bioprinting of human tissues, raised US $20m in Series A financing round.
The round was led by Radical Ventures with participation from existing and new investors, including Pangaea Ventures, Pallasite Ventures, and Rhino Ventures.
The company will use this capital to advance multiple tissue therapeutic programs, expand its technology platform capabilities, and grow its team.
Led by Tamer Mohamed, CEO, Aspect Biosystems provides a technology platform that enables the creation of living human tissues with flexibility and precision. In addition to its internal tissue therapeutic programs for regenerative medicine, the company works with its global partners to create solutions for the medical research and clinical practice.
The company has over 30 employees.